HENDERSON, Nev., Sept. 17, 2026 /PRNewswire/ --  VolitionRx Limited (NYSE AMERICAN: VNRX) ( XASE: VN

French Government-Funded €6.3 million (~$7.3 million) Consortium Selects Volition's Nu.Q® NETs A

French Government-Funded €6.3 million (~$7.3 million)  Consortium Selects Volition's Nu.Q® NETs Assa

VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today ann

Reduces Equity Overhang HENDERSON, Nev., Sept. 14, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AME

Targets $36 Billion TAM in Early Cancer Detection and MRD. HENDERSON, Nev.

Shares of VolitionRX Limited (NYSEAMERICAN:VNRX - Get Free Report) crossed below its 50-day moving a

Gainers Redhill Biopharma (NASDAQ:RDHL) shares increased by 96.7% to $1.3 during Monday's pre-m

Gainers Aardvark Therapeutics (NASDAQ:AARD) shares increased by 8.5% to $6.28 during Friday's a

Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 41.4% to $7.29 during Friday's pre-mark

Gainers Celularity (NASDAQ:CELU) stock moved upwards by 134.0% to $2.06 during Thursday's regul

US stocks traded higher with Nasdaq up 200 points. Dow down 0.01%, Nasdaq up 0.77%, and S&P 500

Gainers VolitionRX (AMEX:VNRX) shares increased by 102.2% to $0.69 during Thursday's pre-market

VolitionRx Limited (NYSE:VNRX) stock is surging on Thursday after the diagnostics company reported a

VolitionRx reports 112% revenue growth in H1 2026 while advancing its Nu.Q diagnostic platforms acro

Salesforce Inc (NYSE: CRM) stock rose on good Q2 results and raised FY27 guidance, while other tech

112% H1 Revenue Growth, Advance Toward $5 Million Veterinary Milestone, Newly Announced Collaboratio

112% H1 Revenue Growth, Advance Toward $5 Million Veterinary Milestone, Newly Announced Collaboratio

Entitled "H3.1 Nucleosomes to Predict Renal Replacement Therapy and Mortality in Sepsis—A Second

Published in Critical Care Medicine , findings confirm high-predictive accuracy for severe sepsis ou

Gainers Nuwellis (NASDAQ:NUWE) stock increased by 27.2% to $1.22 during Wednesday's pre-market

VolitionRx Limited (VNRX) Q2 2026 Earnings Call Transcript

On Friday, VolitionRX (AMEX:VNRX) discussed second-quarter financial results during its earnings cal

VolitionRX (AMEX:VNRX) reported quarterly losses of $(0.85) per share which missed the analyst conse

Conference call to discuss financial and operational results scheduled for Friday, August 14 at 8:30

This new lateral flow finger prick sample test could be used to rapidly identify high-risk patients

Removes Centralized Lab Dependency for $3.8 Billion Global Addressable Market for NETosis Testing HE

Conference call to take place on Friday, August 14 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.

Targets $36 Billion TAM in Early Cancer Detection and MRD. Company in active discussions with global

Consistent international data positions Nu.Q® H3.1 as a potential "game changer" in sepsis managemen

The clinical paper entitled "Prognostic value of circulating H3K27Me3-nucleosomes in newly diagn

HENDERSON, Nev., July 7, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"),

VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces

HENDERSON, Nev., June 17, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition")

$4.6 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upo

https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/

Seeks Strategic Partners to Deploy Nu.Q® Platform in Outbreak Zones HENDERSON, Nev., June 3, 2026 /P

Update Highlights 300% Q1 Revenue Growth, Advance Toward $5 Million Veterinary Milestone, and Active

VolitionRx Limited (VNRX) Q1 2026 Earnings Call Transcript

VolitionRX (AMEX:VNRX) reported quarterly losses of $(0.97) per share which missed the analyst conse

VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces

VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces

HC Wainwright & Co. analyst Yi Chen maintains VolitionRX (AMEX:VNRX) with a Buy and lowers th